Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.97

-2.0%

Dec 29 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: technetium who wrote (22515)	1/15/2007 6:29:40 PM
From: DewDiligence_on_SI	Read Replies (1) of 52153

SBS.TO – Will plants compete -- what about glycosylation and protein folding and isolation? SBS claims that folding has been demonstrated to be identical to that of endogenous insulin. Insulin is not glycosylated so that’s not an issue in this program. By isolation I assume you mean isolation of the insulin gene from other crops. This remains at least a theoretical concern for all transgenic plants grown outdoors, but there are no special problems in this regard for the SBS insulin program. SBS can grow their insulin-producing plants indoors. (In fact, that’s where the supplies used in clinical trials to date have been grown.) Growing indoors reduces the yield, but this can be mitigated to some degree with horticultural adjustments. Still, I doubt the company would pursue commercialization if all product were required to be grown indoors. Regards, Dew

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next